2024-09-02 - Analysis Report
##  Johnson & Johnson (JNJ) Stock Analysis:

**Company Overview:**  Johnson & Johnson is a multinational pharmaceutical, medical device, and consumer packaged goods conglomerate, known for its diverse product portfolio and strong brand recognition.

**1. Performance vs. S&P 500 (VOO):**

* **JNJ Cumulative Return:** 19.88%
* **VOO Cumulative Return:** 89.66%
* **Relative Performance:** JNJ has underperformed VOO significantly with a cumulative return difference of -69.78%. This places JNJ at the 12.84% percentile of historical relative performance, indicating a relatively weak performance compared to the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $165.86
* **5-Day Moving Average:** $164.31
* **20-Day Moving Average:** $161.22
* **60-Day Moving Average:** $154.17

The stock price is currently above all three moving averages, indicating a potential short-term bullish trend. However, the short-term momentum may be fading as the 5-day moving average is starting to flatten.

**3. Technical Indicators:**

* **RSI:** 74.35 - The RSI is currently in overbought territory (above 70), suggesting that the stock may be due for a correction in the near future.
* **PPO:** 0.09 - The PPO is positive, indicating a potential bullish trend. However, it is relatively low, indicating a lack of strong momentum.
* **Delta_Previous_Relative_Divergence:** -9.44 - The negative value suggests a short-term bearish trend, indicating a potential decrease in relative price strength.
* **Expected Return:** 11.93% - This indicates a potential 5-year projected return for an investor who chooses to invest in JNJ at the current price.

**4. Recent Earnings and Outlook:**

| Date        | EPS    | Revenue    |
|-------------|--------|------------|
| 2024-07-25  | 1.95   | $22.45 B  |
| 2024-05-01  | 1.35   | $21.38 B  |
| 2024-02-16  | 1.68   | $21.39 B  |
| 2023-10-27  | 10.32  | $21.35 B  |
| 2024-02-16  | 10.32  | $21.35 B  |

The most recent earnings report shows that JNJ exceeded earnings estimates by a significant margin. Revenue slightly missed estimates, but overall, the company demonstrated a strong performance. 

**5. Summary:**

Johnson & Johnson currently trades at a significant discount to the S&P 500, indicating potential value for long-term investors. However, the company faces headwinds in the form of a high RSI, a negative Delta_Previous_Relative_Divergence, and a relatively low PPO. Despite these short-term indicators, JNJ's recent earnings performance and strong brand reputation suggest potential upside. Investors should monitor the stock closely for signs of a correction before making any investment decisions.

**6. Overall, JNJ is a large-cap, dividend-paying stock with a long history of consistent performance. While its recent relative performance against the S&P 500 has been lackluster, its solid financial performance and strong brand recognition make it a potentially attractive investment for long-term investors. Investors should consider the technical indicators and recent earnings performance when making investment decisions.**